Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tislelizumab by BeiGene for Gallbladder Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Gallbladder Cancer. According to GlobalData, Phase II...
Tislelizumab by BeiGene for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...
Tislelizumab by BeiGene for Androgen-Sensitive Prostate Cancer: Likelihood of Approval
Tislelizumab is under clinical development by BeiGene and currently in Phase II for Androgen-Sensitive Prostate Cancer. According to GlobalData, Phase...